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an aneurysm, but rather revealed an abdominal massmeasuring 20 cm.
Her primary care physician obtained a computed tomography (CT) scanArticle history:
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of her abdomen and pelvis, which revealed an 18 cm abdominal mass
without evidence of lymphadenopathy or other metastases. A uterus
was not visualized (Fig. 1). Shewas then referred to a local gynecologist,
where a pelvic ultrasound was preformed. This conﬁrmed a large, solid
hypoechoicmasswith venous bloodﬂow. Although nouterus or ovaries
were appreciated on this study, there was still suspicion for a gyneco-
logic etiology. A CA-125 level was obtained (21.6 units/mL), and she
was referred to the university for further work-up.
At the gynecologic oncology clinic, the patient stated she hadnormal bowel and bladder function, and denied any vaginal bleedingIntroduction
Androgen insensitivity syndrome (AIS) is a disease that can be
X-linked recessive or sporadic in nature. Patients with complete AIS
are phenotypically female individuals with an XY genotype. During
embryonic development, the testicular tissue present in patients
with AIS produces Mullerian Inhibiting Substance, which blocks the
development of the upper one third of the vagina, uterus and ovaries,
while a lack of androgen receptors results in female-appearing external
genitalia. Complete AIS patients tend to present as amenorrheic females
during adolescence. This case report presents a unique situation inwhich
a public health screening campaign, for abdominal aortic aneurysms, led
to an incidental ﬁnding and work-up resulting in two separate, yet
related diagnoses: androgen insensitivity syndrome (AIS) and sertoli
cell adenoma. This case also highlights the importance of a comprehen-
sive physical examinationwith emphasis onwide differential diagnosis.
It underscores the importance of considering the complicated ethics
surrounding patient disclosurewhen dealingwith a sensitive diagnosis.
Case
A 65 year-old female was in her usual state of health when she
underwent an abdominal ultrasound as part of a community screening
program for abdominal aortic aneurysms. The ultrasound did not showSchool of Medicine and Public
, USA. Fax: +1 608 265 6572.
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-ND license.symptoms of early satiety and bloating for two weeks. She denied
any nausea, vomiting, fever, night sweats or weight loss. She had
or discharge. Of note, her past medical history was signiﬁcant for
amenorrhea and a subsequent diagnosis of “congenital absence of a
uterus” as a teenager. She did not recall any subsequent work up
after this diagnosis and stated she went yearly to her primary care
physician for a well woman exam. Of note, when speaking with her
primary care doctor to discuss her case, it was mentioned that the
patient consistently declined the pelvic examination portion of her
yearly exam. Her past surgical history was signiﬁcant for an appen-
dectomy. She denied any family history signiﬁcant for gynecologic
or other malignancies. Her general appearance was one of a pheno-
typic female including normal breast development. However, of
note, her height was 180 cm (5′ 11″) and weight was 156.4 kg
(344.8 lb). The abdominal examination revealed a soft, obese abdomen
without any palpable masses. Pelvic examination demonstrated a com-
plete lack of pubic hair but otherwise normal appearing external genitalia.
Upon separation of the labia and visualization of the urethra and vagina, a
shallow, blind pouchwas noted thatmeasured 1 cm in depth. The clitoris
was smaller than normal size. Rectal examination failed to reveal any
masses.
Magnetic resonance imaging was obtained to better evaluate
pelvic anatomy and characteristics of the mass. This showed a
20×18.2×13.6 cm solid pelvic mass extending into the abdomen
(Fig. 2). Gonads were visualized bilaterally at the inferior aspect
of the mass. No uterus or upper vagina was identiﬁed, and the
tumor appeared well circumscribed without invasion into sur-
rounding structures. Laboratory tests were ordered including a
chromosomal analysis, which revealed an XY karyotype. Other
abnormal assays included elevated free and total testosterone
(387.6 pg/mL and >1500 ng/dL respectively), and a markedly
high Inhibin B (>5000 pg/mL). The remainder of the patient's
labs, alpha fetoprotein (181 U/L), quantitative total beta HCG
Fig. 1. CT scan of abdomen and pelvis. CT scan image of the abdomen and pelvis dem-
onstrating a large pelvic mass.
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Upon reviewing the laboratory results and physical examination,
a diagnosis of complete AIS was made without resolving the etiol-
ogy of the mass.
The diagnosis of AIS presented a unique and complicated situation
because of the patient's age and late presentation. The patient had
lived her life not knowing the medical reason behind her lack of uterus
and the consequences of this diagnosis. The hospital's ethics committee
was consulted to discuss the importance of diagnosis disclosure, and
how to best relay the information to the patient. The committee
unanimously agreed that full disclosure was essential. They added
that the best way to inform the patient was not to deny her status
as a female, but rather to inform her of her genetic composition
and the likely etiologies of her pelvic mass. It was also agreed upon
that providing the patient with sufﬁcient support, including a health
psychologist familiar with the syndrome, was imperative. The patient
returned to clinic for pre-operative evaluation,was told of her diagnosis
of AIS and of the importance of surgical removal of the mass as well asFig. 2. MRI of abdomen and pelvis. MRI image of the abdomen and pelvis showing a
large, solid, well circumscribed mass.the gonads. She was fully consented for the procedure. She then met
with an appropriate psychologist to provide emotional support.
The patient underwent exploratory laparotomy, bilateral gonadal
resection which included resection of the pelvic mass, uterine remnant
resection, adhesiolysis and peritoneal washings. Intra-operative ﬁnd-
ings included a large pelvic mass, arising from the left gonad, solid in
consistency, with small adhesions to the right and left pelvic sidewalls
(Fig. 3). The uterine remnant was found to be distally attached to the
right gonad. It was transected from its distal attachment and suture
ligated. Frozen section revealed a 2.8 kg homogenous solid mass, with
sertoli cell proliferation and no features of carcinoma. Because of these
ﬁndings, staging was not preformed. The patient tolerated the proce-
dure well and was discharged home on post-operative day four. After
an uncomplicated surgical recovery, she followed upwith reproductive
endocrinology and the health psychologist for long-term management
of her AIS. She was found to be coping considerably well with the new
diagnosis, with a solid social support system. Her main concern was
why this diagnosis had not been made years prior. Final pathology
revealed a left gonadwithwell-differentiated sertoli cell adenomamea-
suring 19.6 cmwithout surface involvement. The right gonadwas com-
posed of ovarian-type stroma with areas of ﬁbrosis, admixed with
testicular tubules containing sertoli cells but no identiﬁable sper-
matogonia. The suspected uterine remnant was found to have be-
nign smooth muscle.
Comment
The etiology of a congenitally absent uterus, blind short vaginal
pouch, and lack of pubic hair is most likely complete or partial AIS.
Patients with partial AIS usually have some features of masculinization
(e.g., enlarged clitoris and virilization) and this patient did not. Patients
with complete AIS have no androgen receptor activity and therefore are
phenotypically female, as virilization requires excess androgens with
functional receptors. Complete AIS patients do tend to have tall stature,
lack of androgen effect in their hair distribution, shortened vagina, and
infertility due to the absence of a uterus; with the latter two being a
result of the presence of Mullerian Inhibiting Substance produced by
the testes during development. Notably, on physical examination, all
of these characteristics were present in our patient. Additional possibili-
ties in the differential diagnosis included congenital abnormalities such
as vaginal agenesis andmicroperforate hymen. The patient lacked classic
ovaries on imaging, essentially ruling out vaginal agenesis, and the
vaginal anatomy was not consistent with imperforate hymen.
AIS is a diseasemost commonly diagnosed in adolescents during the
initial presentation of primary amenorrhea. By diagnosing AIS early,
patients have more time to process the psychological and physical
implications of the disease. Cases of AIS diagnosed beyond adolescence
are rare. Similar to our patient, Lentz and Cappellari in 1998 reportedFig. 3. Gross image of the tumor.
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presenting with abdominal pain, swelling and a pelvic mass (Lentz
and Cappellari, 1998).
Early diagnosis allows patients to undergo the recommended
preventative gonadectomy to prevent malignancy from occurring
(Cassio et al., 1990). In a case series by Rutgers and Scully, 10 of
their 43 patients (23%), were found to have sertoli cell adenomas
(Rutgers and Scully, 1991). Seven of the cases had a uterine remnant
as was also seen in this case (Rutgers and Scully, 1991). This is likely
due to varying levels of Mullerian Inhibitory Substance and excess
estrogen during development (Rutgers and Scully, 1991; Oka et al.,
1984). Other case reports involving patients with AIS have found
Sertoli–Leydig cell tumors and malignant Leydig cell tumors (Rutgers,
2011). The microscopic pathology of the gonads found in patients
with AIS tends to be consistent with tubulostromal gonadal tissue
with Sertoli or Leydig cells present and occasionally with spindle cell
stroma representing ovarian stroma. Spermatogonia were found in
12% of cases by Rutgers and Scully (1991). This patient's gonadal tissue
was found to be ovarian-type stroma with areas of ﬁbrosis, admixed
with testicular tubules containing sertoli cells but no identiﬁable sper-
matogonia, as well as small nests of steroid producing cells and Leydig
cells.
With the diagnosis of AIS so late in life, disclosure becomes complex.
It is challenging to inform a female adult patient that she is a genotypic
male, especially when she lacked any suspicion of such a diagnosis.
Conn et al. in 2005, presented the ethics regarding diagnosis disclosure
of AIS (Conn et al., 2005). They concluded that because of patient justice
and the right to patient autonomy, women should be told of their
diagnosis of AIS immediately. Women with AIS are not men. They
are women who have a Y-chromosome (Jorgensen et al., 2010).
Their syndrome provides them with unique challenges both physically
and psychologically that deserve attention, whether the diagnosis is
made in adolescence or in late adulthood.
An intriguing feature of this case is that both the discovery of a pelvic
mass and the eventual diagnosis of AIS were found incidentally due to
community screening for abdominal aortic aneurysm. Public health
screening campaigns are used as a strategy to detect certain diseases
and conditions within target populations. While they are popular as an
approach to preventive medicine, the US Preventive Services Task
Force does not recommend speciﬁc screening of women for abdominalaortic aneurysms (AAA) due to lack of signiﬁcant beneﬁt and low preva-
lence of AAA in women (Andermann, 2012). Once again, in reviewing
the literature on abdominal aortic aneurysm screening, there is paucity
of data on the prevalence of incidental, but clinically signiﬁcant, ﬁndings
(Andermann, 2012; Darwood and Brooks, 2012). This topic needs addi-
tional study to further clarify the implications of community radiologic
screenings.
In conclusion, this case demonstrates a unique situation: delayed
diagnosis of complete AIS found incidentally at a community screening,
with concurrent sertoli cell adenoma. It is rare for a woman beyond her
teen years to be diagnosed with AIS. With late diagnosis, disclosure is
just as critical. A great deal of support is required, as both the psycholog-
ical and physical aspects are complex.
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